Diabeloop Presents New Real-Life Results of DBLG1® System
Retrieved on:
Thursday, April 28, 2022
Solution, Intelligence, Artificial intelligence, Life, DOI, Diabetes, CEO, Personality, T1D, Patient, Glycated hemoglobin, GLOBE, ATTD, Insight, Diabetes Care, Quality of life, Technology, Dizziness, Meal, Data, WP7, Spotify, Hypoglycemia, Conditional sentence, University, AID, Come, Medical device, Pharmaceutical industry, Health insurance
PARIS, April 28, 2022 (GLOBE NEWSWIRE) -- At ATTD 2022 - Diabeloop, a pioneer in therapeutic artificial intelligence for diabetes management, presents today new results from a real-life cohort in Germany.
Key Points:
- PARIS, April 28, 2022 (GLOBE NEWSWIRE) -- At ATTD 2022 - Diabeloop, a pioneer in therapeutic artificial intelligence for diabetes management, presents today new results from a real-life cohort in Germany.
- DBLG1 users in Germany included in the real-life cohort benefit from basic support at initialization.
- This demonstrates the ease of use of Diabeloop's automated and personalized insulin delivery system and its interface.
- DOI: 10.1016/S2589-7500(19)30003-2
3) C. Amadou et al., Diabeloop DBLG1 Closed-loop system enables patients with Type 1 diabetes to significantly improve their glycemic control in real-life situations without serious adverse events, Diabetes Care 2021 Jan; dc201809.